Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
34 Analysts have issued a Regeneron Pharmaceuticals forecast:
34 Analysts have issued a Regeneron Pharmaceuticals forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 14,248 14,248 |
3%
3%
|
|
| Gross Profit | 12,293 12,293 |
2%
2%
|
|
| EBITDA | 4,459 4,459 |
4%
4%
|
|
| EBIT (Operating Income) EBIT | 3,934 3,934 |
6%
6%
|
|
| Net Profit | 4,578 4,578 |
2%
2%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
| Head office | United States |
| CEO | Leonard Schleifer |
| Employees | 15,158 |
| Founded | 1988 |
| Website | www.regeneron.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


